Claxton, K. (orcid.org/0000-0003-2002-4694), McCabe, C., Tsuchiya, A. and Raftery, J. (2006) Drugs for exceptionally rare diseases: a commentary on Hughes et al. Discussion Paper. QJM
This is the latest version of this eprint.
Recently in this journal, Hughes and colleagues discussed special funding status to ultra-orphan drugs. They concluded that there should be a uniform policy for the provision of orphan drugs across Europe; that complete restriction was impractical, and that UK policy should aspire to the values of the EU directive on orphan drugs. We critically assess these arguments, demonstrating that they failed to justify special status for treatments for rare diseases.
|Item Type:||Monograph (Discussion Paper)|
|Institution:||The University of York|
|Academic Units:||The University of York > Economics and Related Studies (York)|
|Depositing User:||ScHARR / HEDS (Sheffield)|
|Date Deposited:||14 Jul 2010 15:42|
|Last Modified:||23 May 2016 00:24|
Available Versions of this Item
Drugs for exceptionally rare diseases: a commentary on Hughes et al. (deposited 23 Jun 2010 14:12)
- Drugs for exceptionally rare diseases: a commentary on Hughes et al. (deposited 14 Jul 2010 15:42) [Currently Displayed]